Actuate Therapeutics Inc
ACTU
Company Profile
Business description
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Contact
1751 River Run
Suite 400
Fort WorthTX76107
USAT: +1 817 887-8455
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
10
Stocks News & Analysis
stocks
3 global ‘buy the dip’ candidates with wide moats
Does recent share price weakness spell opportunity in these three high-quality companies? Our analysts think so.
stocks
What next for Nine Entertainment after Domain payout?
The media group has excelled in controlling what it can control. Now the focus shifts to capital deployment.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,071.40 | 9.10 | -0.10% |
| CAC 40 | 7,823.52 | 62.20 | 0.80% |
| DAX 40 | 23,703.65 | 70.70 | 0.30% |
| Dow JONES (US) | 46,108.00 | 617.08 | 1.36% |
| FTSE 100 | 9,297.58 | 72.19 | 0.78% |
| HKSE | 26,086.32 | 113.94 | -0.43% |
| NASDAQ | 22,043.07 | 157.01 | 0.72% |
| Nikkei 225 | 44,372.50 | 534.83 | 1.22% |
| NZX 50 Index | 13,229.15 | 0.00 | 0.00% |
| S&P 500 | 6,587.47 | 55.43 | 0.85% |
| S&P/ASX 200 | 8,805.00 | 8.80 | -0.10% |
| SSE Composite Index | 3,875.31 | 63.09 | 1.65% |